In vitro activity of garenoxacin tested against a worldwide collection of ciprofloxacin-susceptible and ciprofloxacin-resistant Enterobacteriaceae strains (1999-2004)

Diagnostic Microbiology and Infectious Disease

Volumn 58, Issue 1, 2007, Pages 27-32

  Sader, Helio S ^a,b   Fritsche, Thomas R ^a   Jones, Ronald N ^a,c  

^a JMI LABORATORIES   (United States)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CLSI; Enterobacteriaceae; Fluoroquinolones; Garenoxacin; Resistance; Topoisomerases

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; CEPHALOSPORIN; CIPROFLOXACIN; CLAVULANIC ACID; COTRIMOXAZOLE; GARENOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ARTICLE; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIUM ISOLATION; DRUG ACTIVITY; DRUG SENSITIVITY; ENTEROBACTER; ENTEROBACTERIACEAE; ESCHERICHIA COLI; HUMAN; IN VITRO STUDY; METHODOLOGY; MINIMUM INHIBITORY CONCENTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SALMONELLA; SHIGELLA; SKIN INFECTION; SOFT TISSUE INFECTION; URINARY TRACT;

ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; EUROPE; FLUOROQUINOLONES; HUMANS; LATIN AMERICA; MICROBIAL SENSITIVITY TESTS; NORTH AMERICA; POPULATION SURVEILLANCE;

EID: 34247899136     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2006.12.006     Document Type: Article

References (19)

1. Andersson M.I., and MacGowan A.P. Development of the quinolones. J. Antimicrob. Chemother. 51 Suppl 1 (2003) 1-11
2. Branger C., Zamfir O., Geoffroy S., Laurans G., Arlet G., Thien H.V., Gouriou S., Picard B., and Denamur E. Genetic background of Escherichia coli and extended-spectrum β-lactamase type. Emerg. Infect. Dis. 11 (2005) 54-61
3. CLSI. Clinical and Laboratory Standards Institute. M7-A7, Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard. 7th ed. (2006), CLSI, Wayne, PA
4. CLSI. Clinical and Laboratory Standards Institute. M100-S16, Performance Standards for Antimicrobial Susceptibility Testing; Sixteenth Informational Supplement (2006), CLSI, Wayne, PA
5. Donati M., Pollini G.M., Sparacino M., Fortugno M.T., Laghi E., and Cevenini R. Comparative in vitro activity of garenoxacin against Chlamydia spp. J. Antimicrob. Chemother. 50 (2002) 407-410
6. Fung-Tomc J.C., Minassian B., Kolek B., Huczko E., Aleksunes L., Stickle T., Washo T., Gradelski E., Valera L., and Bonner D.P. Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756. Antimicrob. Agents Chemother. 44 (2000) 3351-3356
7. Hansen G.T., and Blondeau J.M. Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens. J. Chemother. 17 (2005) 484-492
8. Hyle E.P., Lipworth A.D., Zaoutis T.E., Nachamkin I., Bilker W.B., and Lautenbach E. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae: variability by site of infection. Arch. Intern. Med. 165 (2005) 1375-1380
9. Jones R.N., and Biedenbach D.J. Comparative activity of garenoxacin (BMS 284756), a novel desfluoroquinolone, tested against 8,331 isolates from community-acquired respiratory tract infections: North American results from the SENTRY Antimicrobial Surveillance Program (1999-2001). Diagn. Microbiol. Infect. Dis. 45 (2003) 273-278
10. Jones R.N., Pfaller M.A., and Stilwell M. Activity and spectrum of BMS 284756, a new des-F (6) quinolone, tested against strains of ciprofloxacin-resistant Gram-positive cocci. Diagn. Microbiol. Infect. Dis. 39 (2001) 133-135
11. Kirby J.T., Mutnick A.H., Jones R.N., Biedenbach D.J., and Pfaller M.A. Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000). Diagn. Microbiol. Infect. Dis. 43 (2002) 303-309
12. Liebetrau A., Rodloff A.C., Behra-Miellet J., and Dubreuil L. In vitro activities of a new des-fluoro(6) quinolone, garenoxacin, against clinical anaerobic bacteria. Antimicrob. Agents Chemother. 47 (2003) 3667-3671
13. Lister P.D. Impact of AUC/MIC ratios on the pharmacodynamics of the des-F(6) quinolone garenoxacin (BMS-284756) is similar to other fluoroquinolones. J. Antimicrob. Chemother. 51 (2003) 199-202
14. Mutnick A.H., Rhomberg P.R., Sader H.S., and Jones R.N. Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001). J. Antimicrob. Chemother. 53 (2004) 290-296
15. Pereyre S., Renaudin H., Bebear C., and Bebear C.M. In vitro activities of the newer quinolones garenoxacin, gatifloxacin, and gemifloxacin against human mycoplasmas. Antimicrob. Agents Chemother. 48 (2004) 3165-3168
16. Rolston K.V., Frisbee-Hume S., LeBlanc B.M., Streeter H., and Ho D.H. Antimicrobial activity of a novel des-fluoro (6) quinolone, garenoxacin (BMS-284756), compared to other quinolones, against clinical isolates from cancer patients. Diagn. Microbiol. Infect. Dis. 44 (2002) 187-194
17. Sader H.S., Biedenbach D.J., and Jones R.N. Global patterns of susceptibility for 21 commonly utilized antimicrobial agents tested against 48,440 Enterobacteriaceae in the SENTRY Antimicrobial Surveillance Program (1997-2001). Diagn. Microbiol. Infect. Dis. 47 (2003) 361-364
18. Streit J.M., Jones R.N., Sader H.S., and Fritsche T.R. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). Int. J. Antimicrob. Agents 24 (2004) 111-118
19. Zhao X., Eisner W., Perl-Rosenthal N., Kreiswirth B., and Drlica K. Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 47 (2003) 1023-1027